Ascelia Pharma sees potential FDA approval path after NDA rejection

Ascelia Pharma, whose stock collapsed after the FDA rejected its NDA application, now reports signs of a possible path to approval. The company's statement is preliminary and lacks specifics, leaving the regulatory outcome uncertain. This matters for investors holding the stock and for patients awaiting the drug.